Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - NeuBase Therapeutics, Inc. | ex-99_1.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2014
Ohr
Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 333-88480 | #90-0577933 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 800 3rd Avenue, 11th Floor, New York, NY | 10022 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212)-682-8452
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Items.
On May 9, 2014, the Company issued a press release announcing the initiation of study OHR-005, a randomized, placebo controlled, phase II investigator sponsored trial evaluating Squalamine eye drops for the treatment of diabetic macular edema.
A copy of the press release is being furnished as exhibit 99.1 to form 8K.
| Exhibit No. | Description | |
| 99.1 | Press Release Dated May 9, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorize
| [OHR PHARMACEUTICAL, INC. | ||
| Dated: May 9, 2014 | By: | /s/ Irach Taraporewala |
| Dr. Irach Taraporewala, President and CEO | ||